Status Awaiting development
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 11905

Project Team

Project lead Abbie Stephens

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
11 April 2025 This topic will now be progressed as a Multiple Technology Appraisal (MTA) alongside the following topic; Semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458] The Invitation to Participate (ITP) will now be issued week commencing 07 July 2025 and the MTA title and ID number is: Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458] Details of the MTA process can be found within the health technology evaluation manual on our website.
13 September 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual